# Pulmonology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: John Locke (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN001-SYN-TD
- Date: 1692-03-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Ambrose Nwankwo-Fairfax, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Prudence Hartwell-Osei, MD

## Reason for consultation

A 59-year-old never-smoker with a cough since his late thirties and wheeze and breathlessness, worse every winter, in city air, and by open coal and wood fires at home. Please confirm the diagnosis (asthma, COPD from non-tobacco exposures, or both), advise on CT, and recommend treatment and pulmonary rehabilitation. **S**

## History

Mr. Locke is seen at the request of Dr. Hartwell-Osei. He has had a cough since his late thirties, with wheeze and breathlessness that have grown over the years; symptoms are worst in winter, in cold air, in the city, and by smoky fires, and ease in summer and in the country. He has never smoked or vaped and has had no occupational dust or fume exposure. He lived about 30 years in a large city near main roads and for the past year has lodged in a country house with open coal and wood fires, which have been out of use for two weeks. He has had no hemoptysis, fevers, night sweats, weight loss, nasal symptoms, reflux, or breathlessness lying flat. He has never had an oral corticosteroid course or an emergency visit for breathing. On albuterol as needed he uses one or two doses a day. His father and brother died of consumption. **S**

## Examination

| System | Finding |
|---|---|
| General | Thin, comfortable at rest, speaking in full sentences |
| Respiratory | Prolonged expiration with scattered expiratory wheeze; no crackles; no clubbing; oxygen saturation 95 percent |
| Cardiovascular | Regular rhythm; jugular venous pressure not raised; no edema |
| Ears, nose, and throat | Nasal mucosa normal; no polyps |

BP 120/74 mmHg; pulse 82 bpm; respirations 18/min; temperature 36.5 °C; oxygen saturation 95% on room air; weight 62.1 kg; BMI 19.6 kg/m². All vital signs are synthetic.

## Data reviewed

Spirometry this morning (GLI Global race-neutral equations): FEV1 2.11 L (62 percent predicted) and FVC 3.71 L before bronchodilator, FEV1/FVC 0.57; 15 minutes after albuterol 400 mcg, FEV1 2.49 L (+380 mL, 11 percent of predicted) and FVC 4.02 L, FEV1/FVC 0.62 (lower limit of normal 0.67); DLCO 26.4 mL/min/mmHg (predicted 26.9); FeNO 41 ppb; six-minute walk 430 m with lowest saturation 94 percent. CT of the chest today without contrast, with expiratory images: diffuse bronchial wall thickening and mosaic attenuation with air trapping; no emphysema, bronchiectasis, nodules, or interstitial disease. From the first visit: eosinophils 0.46 x 10^3/uL, IgE 186 IU/mL, alpha-1 antitrypsin 131 mg/dL, NT-proBNP 58 pg/mL, interferon-gamma release assay negative (0.02 IU/mL), and a chest X-ray with mild hyperinflation only. Asthma Control Test 13 today. FEV1 before bronchodilator: 2.11 L (low); FVC before bronchodilator: 3.71 L; FEV1/FVC before bronchodilator: 0.57 (low); FEV1 percent predicted (before bronchodilator): 62% (low); FEV1 after bronchodilator: 2.49 L (low); FVC after bronchodilator: 4.02 L; FEV1/FVC after bronchodilator: 0.62 (low); DLCO: 26.4 mL/min/mm[Hg]; FeNO: 41 [ppb] (high); Six-minute walk distance: 430 m (low); Asthma Control Test: 13. All results are synthetic.

## Assessment

1. **Asthma with persistent airflow limitation, type 2 phenotype** (J45.40). He has airflow limitation that persists after bronchodilator (FEV1/FVC 0.62, below the lower limit of normal and below 0.70) with a large bronchodilator response. GOLD recognizes COPD in never-smokers from air pollution and solid-fuel smoke, so COPD was considered. The weight of evidence is for asthma: onset in his late thirties, symptoms that vary with season, cold, and smoke, a bronchodilator response of 380 mL, FeNO 41 ppb, eosinophils 0.46 x 10^3/uL, a raised IgE, a normal DLCO, and a CT showing airway disease without emphysema. The persistent limitation most likely reflects decades of under-treated asthma with airway remodeling, worsened by pollution and indoor smoke. Treat as asthma: an inhaled corticosteroid is essential, and a long-acting bronchodilator without one is unsafe. Tuberculosis, alpha-1 antitrypsin deficiency, heart failure, and bronchiectasis are excluded. **S**
2. **Exposure to air pollution and indoor solid-fuel smoke** (Z77.110). Fine particles from coal, wood, and traffic smoke are well-established triggers of asthma symptoms and flares and contribute to lower lung function. Removing indoor solid-fuel smoke is the most effective step within his control; outdoor exposure can be reduced but not removed. **S**

## Recommendations

1. Diagnosis: asthma with persistent airflow limitation, type 2 phenotype; not COPD. Record the reasoning, and repeat spirometry after three months of treatment to find his best lung function.
2. CT was indicated for persistent airflow limitation in a never-smoker and was done today; it shows airway disease without emphysema or bronchiectasis. No further imaging unless new features appear.
3. Start budesonide-formoterol 160/4.5 mcg, two inhalations twice daily and one as needed, no more than 12 a day (GINA track 1, step 4), and stop albuterol. Teach technique with his own device and give a written action plan. If he is not well controlled at three months despite good adherence and technique, add tiotropium 2.5 mcg two inhalations daily; consider a biologic only if he has flares needing oral corticosteroids despite that.
4. Yes: an eight-week pulmonary rehabilitation program, with a six-minute walk before and after.
5. Keep the open fires out of use permanently and heat his rooms another way; HEPA air cleaners in the rooms where he spends most time; check the air quality index daily and avoid outdoor exertion and city trips when it is 101 or more; a well-fitted N95 respirator on unavoidable alert days; walk away from main roads. The WHO 1687 guideline values for PM2.5 (5 ug/m3 annual, 15 ug/m3 over 24 hours) are a useful target for his indoor monitor.
6. Monitoring: Asthma Control Test, technique, adherence, and exposures at every visit; spirometry and FeNO at three months, then every one to two years; home peak flow to set action-plan zones; influenza, COVID-19, and RSV vaccines in the autumn and PCV20 now.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Hartwell-Osei the same day; Mr. Locke agrees with the diagnosis and the plan and asked for a copy of the exposure advice for the household. **S**

## Follow-up

Primary care continues with Dr. Hartwell-Osei. I will review the three-month spirometry, and would see him again if he is not controlled on add-on tiotropium or has a flare needing oral corticosteroids. **S**

## Guideline basis

- Global Strategy for Asthma Management and Prevention, 2025 update (2025), Global Initiative for Asthma
- 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020), National Heart, Lung, and Blood Institute (J Allergy Clin Immunol 2020;146(6):1217-1270)
- Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025), Global Initiative for Chronic Obstructive Lung Disease
- Stanojevic S, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022;60(1):2101499 (PMID 34949706) (2022), European Respiratory Society and American Thoracic Society
- Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023), American Thoracic Society
- Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine 2023;208(4):e7-e26)
- WHO global air quality guidelines: particulate matter (PM2.5 and PM10), ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide (2021), World Health Organization
- Carlsten C, et al. Personal strategies to minimise effects of air pollution on respiratory health: advice for providers, patients and the public. Eur Respir J 2020;55(6):1902056 (PMID 32241830) (2020), European Respiratory Society
- AQI Basics (2026), United States Environmental Protection Agency (AirNow)
